• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Comparable regional therapeutic effects between neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy for locally advanced lower rectal cancer in terms of histopathological analysis.就组织病理学分析而言,新辅助化疗与新辅助放化疗对局部晚期低位直肠癌的区域治疗效果相当。
Mol Clin Oncol. 2019 Jun;10(6):619-624. doi: 10.3892/mco.2019.1835. Epub 2019 Mar 28.
2
Meta-analysis of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced rectal cancer.局部晚期直肠癌新辅助化疗与新辅助放化疗的Meta分析。
World J Surg Oncol. 2021 May 5;19(1):141. doi: 10.1186/s12957-021-02251-0.
3
Neoadjuvant Chemotherapy or Neoadjuvant Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: Real-World Data Comparison from A Japanese Nationwide Study.新辅助化疗或新辅助放化疗治疗食管鳞癌患者:来自日本全国性研究的真实世界数据比较。
Ann Surg Oncol. 2023 Sep;30(9):5885-5894. doi: 10.1245/s10434-023-13686-y. Epub 2023 Jun 1.
4
Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery.新辅助化疗和放化疗对边界可切除胰腺癌的临床影响:884 例胰腺外科专科医院患者的分析。
Ann Surg Oncol. 2019 Jun;26(6):1629-1636. doi: 10.1245/s10434-018-07131-8. Epub 2019 Jan 4.
5
Neoadjuvant chemoradiotherapy followed by D2 gastrectomy in locally advanced gastric cancer.局部进展期胃癌先行新辅助放化疗,然后行D2胃切除术。
World J Gastroenterol. 2015 Mar 7;21(9):2711-8. doi: 10.3748/wjg.v21.i9.2711.
6
Neoadjuvant Chemotherapy Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma.食管鳞状细胞癌患者的新辅助化疗及放化疗
Anticancer Res. 2018 Dec;38(12):6809-6814. doi: 10.21873/anticanres.13053.
7
Survival after neoadjuvant approaches to gastroesophageal junction cancer.胃食管结合部癌新辅助治疗后的生存情况。
Gastric Cancer. 2020 Jan;23(1):175-183. doi: 10.1007/s10120-019-00980-6. Epub 2019 Jun 22.
8
Comparison of efficacy and safety of preoperative Chemoradiotherapy in locally advanced upper and middle/lower rectal cancer.局部进展期中高位和中低位直肠癌术前放化疗的疗效和安全性比较。
Radiat Oncol. 2018 Mar 27;13(1):53. doi: 10.1186/s13014-018-0987-0.
9
Exercise during and after neoadjuvant rectal cancer treatment (the EXERT trial): study protocol for a randomized controlled trial.新辅助直肠癌治疗期间及之后的运动(EXERT试验):一项随机对照试验的研究方案
Trials. 2018 Jan 12;19(1):35. doi: 10.1186/s13063-017-2398-1.
10
Exercise prehabilitation may lead to augmented tumor regression following neoadjuvant chemoradiotherapy in locally advanced rectal cancer.运动预处理可能会导致局部晚期直肠癌新辅助放化疗后肿瘤消退增强。
Acta Oncol. 2019 May;58(5):588-595. doi: 10.1080/0284186X.2019.1566775. Epub 2019 Feb 6.

引用本文的文献

1
Neoadjuvant chemotherapy versus long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta-analysis of 5,168 cases.新辅助化疗与长程新辅助放化疗治疗局部晚期直肠癌的比较:一项对5168例病例的系统评价和荟萃分析
Front Oncol. 2025 Jun 26;15:1542885. doi: 10.3389/fonc.2025.1542885. eCollection 2025.
2
Short- and long-term outcomes of neoadjuvant chemotherapy compared with neoadjuvant chemoradiotherapy for locally advanced rectal cancer: an updated meta-analysis.新辅助化疗与新辅助放化疗治疗局部晚期直肠癌的短期和长期结局比较:一项更新的荟萃分析
BMC Gastroenterol. 2025 Feb 17;25(1):87. doi: 10.1186/s12876-025-03667-8.
3
Validation of a genome-based model for adjusting radiotherapy dose (GARD) in patients with locally advanced rectal cancer.基于基因组的局部晚期直肠癌患者放疗剂量调整模型(GARD)的验证
Sci Rep. 2024 Sep 16;14(1):21572. doi: 10.1038/s41598-024-72818-w.
4
Neoadjuvant chemotherapy without radiation as a potential alternative treatment for locally advanced rectal cancer: A meta-analysis.新辅助化疗联合放疗作为局部晚期直肠癌潜在替代治疗方案的Meta分析
World J Gastrointest Oncol. 2021 Sep 15;13(9):1196-1209. doi: 10.4251/wjgo.v13.i9.1196.
5
Meta-analysis of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced rectal cancer.局部晚期直肠癌新辅助化疗与新辅助放化疗的Meta分析。
World J Surg Oncol. 2021 May 5;19(1):141. doi: 10.1186/s12957-021-02251-0.

本文引用的文献

1
A Multicenter Phase 2 Study on the Feasibility and Efficacy of Neoadjuvant Chemotherapy Without Radiotherapy for Locally Advanced Rectal Cancer.一项新辅助化疗而不进行放疗治疗局部进展期直肠癌的多中心 2 期研究。
Ann Surg Oncol. 2017 Nov;24(12):3587-3595. doi: 10.1245/s10434-017-5967-3. Epub 2017 Jul 6.
2
Histological differences between preoperative chemoradiotherapy and chemotherapy for rectal cancer: a clinicopathological study.直肠癌术前放化疗与化疗的组织学差异:一项临床病理研究
Pathol Int. 2016 May;66(5):273-80. doi: 10.1111/pin.12409.
3
Early results of multicenter phase II trial of perioperative oxaliplatin and capecitabine without radiotherapy for high-risk rectal cancer: CORONA I study.多中心II期试验:高危直肠癌围手术期使用奥沙利铂和卡培他滨且不进行放疗的早期结果:CORONA I研究
Eur J Surg Oncol. 2016 Jun;42(6):829-35. doi: 10.1016/j.ejso.2016.02.014. Epub 2016 Feb 27.
4
Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer.XELOX 方案联合贝伐珠单抗新辅助化疗治疗局部高危进展期直肠癌
Cancer Chemother Pharmacol. 2014 May;73(5):1079-87. doi: 10.1007/s00280-014-2417-9. Epub 2014 Mar 5.
5
Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.局部进展期直肠癌患者新辅助化疗不常规应用放疗:一项初步试验。
J Clin Oncol. 2014 Feb 20;32(6):513-8. doi: 10.1200/JCO.2013.51.7904. Epub 2014 Jan 13.
6
Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer.II期和III期可切除直肠癌的术前放化疗与单纯放疗对比
Cochrane Database Syst Rev. 2013 Feb 28;2013(2):CD006041. doi: 10.1002/14651858.CD006041.pub3.
7
Investigation of the freely available easy-to-use software 'EZR' for medical statistics.医学统计学中免费易用软件 EZR 的调查研究。
Bone Marrow Transplant. 2013 Mar;48(3):452-8. doi: 10.1038/bmt.2012.244. Epub 2012 Dec 3.
8
Medium-term results of neoadjuvant systemic chemotherapy using irinotecan, 5-fluorouracil, and leucovorin in patients with locally advanced rectal cancer.局部晚期直肠癌患者使用伊立替康、5-氟尿嘧啶和亚叶酸进行新辅助全身化疗的中期结果。
Eur J Surg Oncol. 2010 Nov;36(11):1061-5. doi: 10.1016/j.ejso.2010.05.017. Epub 2010 Jun 9.
9
Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03.术前多模式治疗可改善直肠癌患者的无病生存期:NSABP R-03研究。
J Clin Oncol. 2009 Nov 1;27(31):5124-30. doi: 10.1200/JCO.2009.22.0467. Epub 2009 Sep 21.
10
An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer.新辅助治疗与手术之间间隔超过7周可改善局部晚期直肠癌患者的病理完全缓解率和无病生存率。
Ann Surg Oncol. 2008 Oct;15(10):2661-7. doi: 10.1245/s10434-008-9892-3. Epub 2008 Apr 4.

就组织病理学分析而言,新辅助化疗与新辅助放化疗对局部晚期低位直肠癌的区域治疗效果相当。

Comparable regional therapeutic effects between neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy for locally advanced lower rectal cancer in terms of histopathological analysis.

作者信息

Sato Kentaro, Miura Takuya, Morohashi Satoko, Sakamoto Yoshiyuki, Morohashi Hajime, Yoshida Tatsuya, Hakamada Kenichi

机构信息

Department of Gastroenterological Surgery, Hirosaki University, Graduate School of Medicine, Hirosaki, Aomori 036-8562, Japan.

Department of Pathology and Bioscience, Hirosaki University, Graduate School of Medicine, Hirosaki, Aomori 036-8562, Japan.

出版信息

Mol Clin Oncol. 2019 Jun;10(6):619-624. doi: 10.3892/mco.2019.1835. Epub 2019 Mar 28.

DOI:10.3892/mco.2019.1835
PMID:31031978
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6482387/
Abstract

Neoadjuvant chemoradiotherapy (NACRT) for lower rectal cancer is commonly used in many Western countries. NACRT improves local control, but it may also induce anal dysfunction, postoperative complications, and late effects associated with radiation. Neoadjuvant chemotherapy (NAC) for lower rectal cancer has recently been employed to improve these problems, but the local control effect of NAC when compared with NACRT is controversial. The aim of the present study was to compare the effects of NAC and NACRT using histopathological analysis. The subjects included 16 patients treated with NAC and 10 patients treated with NACRT prior to surgery. Pathological effects on primary lesions and lymph nodes were evaluated based on fibrosis and tumor depth prior to and following preoperative therapy. In the NAC and NACRT groups, the T downgrade rates were 87.5 and 80%, T depth/F depth ratios were 0.61 and 0.73, pathological T downgrade rates were 25 and 40%, pathological complete response rates were 12.5 and 0% for primary lesions and 33.3 and 37.5% for lymph nodes, and the N conversion rates were 80 and 37.5%. There were no significant differences between the groups. These results suggest that the pathological therapeutic effects of NAC were similar to those of NACRT, and NAC may be effective as an alternative therapy to NACRT.

摘要

新辅助放化疗(NACRT)常用于许多西方国家的低位直肠癌治疗。NACRT可改善局部控制,但也可能导致肛门功能障碍、术后并发症以及与放疗相关的晚期效应。近年来,低位直肠癌的新辅助化疗(NAC)被用于改善这些问题,但与NACRT相比,NAC的局部控制效果存在争议。本研究旨在通过组织病理学分析比较NAC和NACRT的疗效。研究对象包括16例术前接受NAC治疗的患者和10例术前接受NACRT治疗的患者。根据术前治疗前后的纤维化和肿瘤深度评估对原发灶和淋巴结的病理影响。在NAC组和NACRT组中,T降期率分别为87.5%和80%,T深度/F深度比分别为0.61和0.73,病理T降期率分别为25%和40%,原发灶的病理完全缓解率分别为12.5%和0%,淋巴结的病理完全缓解率分别为33.3%和37.5%,N转化率分别为80%和37.5%。两组之间无显著差异。这些结果表明,NAC的病理治疗效果与NACRT相似,NAC可能作为NACRT的替代疗法有效。